ml500240d_si_001.pdf (345.41 kB)
Download file

Discovery of 2‑Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

Download (345.41 kB)
journal contribution
posted on 09.10.2014, 00:00 by Stefan Peukert, Richard Hughes, Jill Nunez, Guo He, Zhao Yan, Rishi Jain, Luis Llamas, Sarah Luchansky, Adam Carlson, Guiqing Liang, Vidya Kunjathoor, Mike Pietropaolo, Jeffrey Shapiro, Anja Castellana, Xiaoping Wu, Avirup Bose
The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC50s ≤ 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.

History